Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 10/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10299109 | 0.88 | MEN1 (0.59) | SCDKMT2AMEN1LMNAMAPT | |
| SCHEMBL10009438 | 0.86 | JAK2 (0.57) | SCDKMT2AMEN1LMNAMAPT | |
| SCHEMBL10009298 | 0.85 | LMNA (0.55) | SCDKMT2AMEN1LMNAMAPT | |
| SCHEMBL10008802 | 0.85 | KMT2A (0.66) | SCDKMT2AMEN1MAPTADORA3 | |
| SCHEMBL10008888 | 0.85 | SIRT2 (0.58) | SCDKMT2AMEN1LMNAMAPT | |
| SCHEMBL10008113 | 0.84 | SCD (0.54) | SCDKMT2AMEN1MAPTADORA3 | |
| SCHEMBL10009261 | 0.82 | ABL1 (0.50) | SCDKMT2AMEN1LMNAMAPT | |
| SCHEMBL10007768 | 0.81 | ABL1 (0.61) | SCDKMT2AMEN1LMNAMAPT | |
| SCHEMBL10008763 | 0.81 | MEN1 (0.57) | SCDKMT2AMEN1LMNAMAPT | |
| SCHEMBL10008959 | 0.81 | ABL1 (0.63) | SCDKMT2AMEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883793-B2 | Tubulin inhibitors and methods of using the same | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-11-11 | — | — | US | claimed |
| WO-2012092471-A2 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2012-07-05 | — | — | WO | claimed |
| US-20120172374-A1 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2012-07-05 | — | — | US | claimed |
| US-8883793-B2 | Tubulin inhibitors and methods of using the same | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-11-11 | — | — | US | disclosed |
| US-20120172374-A1 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172374-A1 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | TUBB1, TUBA1C, TUBB | SCD 4391/4885KMT2A 1778/4885MEN1 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.